Key Points
- United Therapeutics CEO Martine Rothblatt sold 9,500 shares on July 10 at an average price of $544.60, generating about $5.17 million in proceeds. After the sale, Rothblatt directly owned 40,513 shares, a 19% reduction in position.
- UTHR stock was down 2.1% and opened at $535.57, trading below its 50-day moving average but above its 200-day average. The company’s market value was about $22.73 billion.
- Analysts remain broadly positive on United Therapeutics, with a consensus rating of “Moderate Buy” and an average target price of $644.82. Recent calls included multiple “outperform” or “buy” ratings, though Bank of America trimmed its target and kept a neutral view.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $544.60, for a total transaction of $5,173,700.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,063,379.80. This trade represents a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
United Therapeutics Stock Down 2.1%
NASDAQ UTHR opened at $535.57 on Tuesday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The stock has a market capitalization of $22.73 billion, a PE ratio of 19.77, a price-to-earnings-growth ratio of 1.80 and a beta of 0.58. The firm has a 50 day moving average of $555.98 and a two-hundred day moving average of $529.73.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to analysts' expectations of $797.40 million. During the same period in the prior year, the company posted $6.63 earnings per share. The company's revenue for the quarter was down 1.6% on a year-over-year basis. On average, equities research analysts expect that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
UTHR has been the topic of several recent analyst reports. Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of United Therapeutics in a research report on Thursday, June 11th. Raymond James Financial started coverage on United Therapeutics in a research report on Friday, April 10th. They set an "outperform" rating and a $700.00 price objective for the company. Royal Bank Of Canada increased their price objective on United Therapeutics from $701.00 to $704.00 and gave the company an "outperform" rating in a report on Tuesday, July 7th. Finally, Bank of America cut their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research report on Friday. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $644.82.
View Our Latest Report on United Therapeutics
Hedge Funds Weigh In On United Therapeutics
Large investors have recently bought and sold shares of the stock. Torren Management LLC purchased a new position in shares of United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management lifted its holdings in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC lifted its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics in the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
